Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Total Non-Current Liabilities data on record, last reported at $18.2 million in Q3 2022.

  • For Q3 2022, Total Non-Current Liabilities changed N/A year-over-year to $18.2 million; the TTM value through Sep 2022 reached $18.2 million, changed N/A, while the annual FY2021 figure was $56.9 million, 81.99% down from the prior year.
  • Total Non-Current Liabilities reached $18.2 million in Q3 2022 per AVIR's latest filing, down from $27.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $315.8 million in Q4 2020 and bottomed at $10.8 million in Q3 2020.
  • Average Total Non-Current Liabilities over 3 years is $123.6 million, with a median of $44.1 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 81.99% in 2021, then tumbled 89.81% in 2022.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $315.8 million in 2020, then tumbled by 81.99% to $56.9 million in 2021, then crashed by 67.97% to $18.2 million in 2022.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $18.2 million in Q3 2022, $27.9 million in Q2 2022, and $31.4 million in Q1 2022.